Table I.
Clinicopathological characteristics of prostate cancer cases according to biomarkers expression.
| Characteristics | n | MT-2A (%) | P | E-cadherin (%) | P | IL-6 (%) | P | Cyclin E (%) | P | PCNA (%) | P | Bcl-2(%) | P |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age | 128 | 61.8±6.5 | 0.469 | 61.9±5.8 | 0.452 | 65.9±9.0 | 0.512 | 67.1±8.3 | 0.396 | 64.2±7.1 | 0.602 | 65.8±6.3 | 0.476 |
| Risk classification | 0.042a | 0.032a | 0.031a | 0.039a | 0.136 | ||||||||
| Low-risk | 54 | 25 (46.3) | 20 (30.0) | 22 (40.7) | 22 (40.7) | 30 (59.3) | 0.299 | 28 (51.9) | |||||
| Intermediate risk | 62 | 36 (58.1) | 33 (53.2) | 30 (48.4) | 35 (56.5) | 28 (43.5) | 35 (56.5) | ||||||
| High-risk | 12 | 8 (66.7) | 7 (58.3) | 7 (58.3) | 8 (66.7) | 5 (33.3) | 5 (41.7) | ||||||
| Pathological stage | 0.015a | 0.012a | 0.019a | 0.043a | 0.026a | 0.011a | |||||||
| pT2a | 24 | 10 (41.7) | 17 (70.8) | 8 (33.3) | 9 (37.5) | 15 (62.5) | 7 (29.2) | ||||||
| pT2b | 32 | 15 (46.9) | 16 (50.0) | 14 (43.8) | 14 (43.8) | 16 (50.0) | 16 (50.0) | ||||||
| pT2c | 51 | 28 (54.9) | 23 (45.1) | 23 (45.1) | 29 (56.9) | 22 (43.1) | 28 (54.9) | ||||||
| pT3a | 15 | 11 (73.3) | 3 (20.0) | 9 (60.0) | 7 (46.7) | 10 (66.7) | 12 (80.0) | ||||||
| pT3b | 6 | 5 (83.3) | 1 (16.7) | 5 (83.3) | 6 (100) | 0 | 5 (83.3) | ||||||
| Surgical margins | 0.116 | 0.631 | 0.197 | 0.642 | 0.134 | 0.453 | |||||||
| Negative | 108 | 60 (55.6) | 51 (47.2) | 48 (44.4) | 55 (50.9) | 53 (49.1) | 57 (52.8) | ||||||
| Positive | 20 | 9 (45.0) | 9 (45.0) | 11 (55.0) | 10 (50.0) | 10 (50.0) | 11 (55.0) |
Values for age are presented as the mean ± standard deviation.
a
P<0.05. MT-2A, metallothionein-2A; IL-6, interleukin 6; PCNA, proliferating cell nuclear antigen; Bcl-2, B cell lymphoma 2.